RemeGen Forecasts 2025 Profit Turnaround on Surging Drug Sales and Global Licensing Deal

RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an announcement.

RemeGen Co., Ltd. has issued preliminary 2025 financial estimates indicating a sharp rebound in performance, with operating revenue expected to reach about RMB3.25 billion, up roughly 89% year on year, and net profit attributable to shareholders projected at around RMB716 million, compared with a substantial loss in 2024. The turnaround is driven by rapid sales growth of its core biologic drugs telitacicept and disitamab vedotin in China, a major global licensing deal granting Vor Biopharma exclusive rights to develop and commercialize telitacicept outside Greater China that boosts technology licensing income and shifts some overseas R&D costs to the partner, as well as internal cost and efficiency measures that have lowered production costs, improved gross margins and reduced sales expenses; even after excluding non-recurring gains, notably from fair-value changes of warrants tied to the licensing transaction, the company expects to move from loss to profit in 2025, signaling a significant improvement in its profitability profile and market positioning.

The most recent analyst rating on (HK:9995) stock is a Hold with a HK$88.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a biopharmaceutical company based in China focused on developing and commercializing innovative biologic therapies. Its core marketed products include telitacicept and disitamab vedotin, with a growing emphasis on both domestic sales in the PRC and global partnering, particularly through out-licensing arrangements for its pipeline assets.

Average Trading Volume: 4,652,921

Technical Sentiment Signal: Buy

Current Market Cap: HK$58.65B

For an in-depth examination of 9995 stock, go to TipRanks’ Overview page.